Calliditas Therapeutics Ab ((CALT)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The recent clinical study update from Calliditas Therapeutics AB focuses on evaluating the safety and tolerability of setanaxib in patients with Alport syndrome. Officially titled A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of the NOX1/4 Inhibitor Setanaxib in Patients With Alport Syndrome, the study aims to assess the drug’s safety compared to a placebo and its potential to preserve kidney function when added to standard care.
Setanaxib, the intervention being tested, is a NOX1/4 inhibitor intended to provide additional therapeutic benefits in preserving kidney function for Alport syndrome patients. It is administered alongside standard care treatments.
The study design is interventional, with a randomized, parallel assignment model. It employs triple masking, meaning the participant, care provider, and investigator are unaware of the treatment assignments. The primary purpose is treatment-focused.
The study began on November 27, 2023, with a primary completion date yet to be disclosed. The last update was submitted on August 11, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
The market implications of this study update could influence Calliditas Therapeutics AB’s stock performance, as positive outcomes may boost investor confidence. The results could also impact the competitive landscape, particularly if setanaxib proves effective in treating Alport syndrome.
The study is ongoing, with further details available on the ClinicalTrials portal.